GSK invests $139 million in Benlysta manufacturing facility

2 May 2017

Britain's largest pharma company GlaxoSmithKline (LSE: GSK) is investing $139 million in its biopharmaceutical manufacturing site in Maryland, USA, to support growing demand for Benlysta (belimumab).

The biologic, a human monoclonal antibody, is approved in an intravenous formulation as a treatment for adult patients with SLE, a certain kind of lupus, who are receiving standard therapy.

A self-injectable, subcutaneous formulation is currently being reviewed by regulators in the USA and Europe, with a decision expected later this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK